Total Payments
$25,159
2023 Payments
$27.92
Companies
15
Transactions
62
Medicare Patients
1,731
Medicare Billing
$132,006
Payment Breakdown by Category
Research$20,284 (80.6%)
Consulting$3,500 (13.9%)
Food & Beverage$768.05 (3.1%)
Travel$606.97 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,284 | 16 | 80.6% |
| Consulting Fee | $3,500 | 2 | 13.9% |
| Food and Beverage | $768.05 | 41 | 3.1% |
| Travel and Lodging | $606.97 | 3 | 2.4% |
Payments by Type
Research
$20,284
16 transactions
General
$4,875
46 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $18,550 | 10 | $0 (2017) |
| Optinose US, Inc. | $2,815 | 13 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $1,734 | 6 | $0 (2019) |
| Sandoz Inc. | $1,500 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $113.48 | 7 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $108.78 | 6 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $67.59 | 4 | $0 (2022) |
| GENZYME CORPORATION | $66.48 | 4 | $0 (2019) |
| Grifols USA, LLC | $45.07 | 2 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $36.77 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $27.92 | 1 | PFIZER INC. ($27.92) |
| 2022 | $62.69 | 4 | AstraZeneca Pharmaceuticals LP ($17.07) |
| 2021 | $120.66 | 6 | Grifols USA, LLC ($45.07) |
| 2020 | $153.63 | 9 | AstraZeneca Pharmaceuticals LP ($37.25) |
| 2019 | $1,633 | 8 | SANOFI-AVENTIS U.S. LLC ($1,582) |
| 2018 | $2,991 | 15 | Optinose US, Inc. ($2,765) |
| 2017 | $20,170 | 19 | Glenmark Pharmaceuticals Inc. ($18,550) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/21/2023 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG, COMIRNATY | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 12/22/2022 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Respiratory | ||||||
| 04/27/2022 | Teva Pharmaceuticals USA, Inc. | AirDuo Digihaler (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Respiratory | ||||||
| 04/18/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: RESPIRATORY | ||||||
| 02/16/2022 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: Immunology | ||||||
| 12/09/2021 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/09/2021 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: Pulmonology | ||||||
| 11/03/2021 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: Immunology | ||||||
| 10/27/2021 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: Immunology and Neurology | ||||||
| 05/27/2021 | USWM, LLC | SYMJEPI (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Immunology | ||||||
| 03/23/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: RESPIRATORY | ||||||
| 11/04/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: Respiratory | ||||||
| 08/19/2020 | Teva Pharmaceuticals USA, Inc. | ProAir Digihaler (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Respiratory | ||||||
| 07/09/2020 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 05/21/2020 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Respiratory | ||||||
| 04/27/2020 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 02/03/2020 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/22/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: RESPIRATORY | ||||||
| 01/09/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2019 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Respiratory | ||||||
| 09/30/2019 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $672.00 | Research |
| Study: A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra • Category: IMMUNOLOGY | ||||||
| 06/30/2019 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $112.20 | Research |
| Study: A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra • Category: IMMUNOLOGY | ||||||
| 06/30/2019 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $14.82 | Research |
| Study: A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra • Category: IMMUNOLOGY | ||||||
| 03/30/2019 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $497.46 | Research |
| Study: A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra • Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $18,550 | 10 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra | SANOFI-AVENTIS U.S. LLC | $1,734 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 13 | 758 | 6,036 | $158,890 | $63,146 |
| 2021 | 12 | 500 | 3,441 | $96,879 | $39,250 |
| 2020 | 11 | 473 | 3,296 | $90,173 | $29,609 |
Total Patients
1,731
Total Services
12,773
Medicare Billing
$132,006
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 148 | 226 | $41,810 | $19,400 | 46.4% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 51 | 2,439 | $26,829 | $7,998 | 29.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 58 | 58 | $15,950 | $6,824 | 42.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 90 | 110 | $13,750 | $6,737 | 49.0% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 73 | 793 | $19,825 | $6,419 | 32.4% |
| 95044 | Test for allergy using skin patch | Office | 2022 | 19 | 1,236 | $13,596 | $5,213 | 38.3% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 28 | 445 | $5,785 | $3,155 | 54.5% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 35 | 353 | $7,060 | $2,326 | 32.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 67 | 99 | $6,237 | $1,985 | 31.8% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 33 | 42 | $2,856 | $1,178 | 41.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 18 | 18 | $1,440 | $782.38 | 54.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 24 | 25 | $2,600 | $732.32 | 28.2% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2022 | 114 | 192 | $1,152 | $396.47 | 34.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 124 | $22,940 | $11,048 | 48.2% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 36 | 1,888 | $20,768 | $6,261 | 30.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 72 | 94 | $11,750 | $5,520 | 47.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 39 | 39 | $10,725 | $4,679 | 43.6% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 60 | 481 | $12,025 | $4,035 | 33.6% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 23 | 356 | $4,628 | $2,569 | 55.5% |
| 95115 | Injection of incremental dosages of allergen | Office | 2021 | 28 | 262 | $5,240 | $1,621 | 30.9% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 44 | 55 | $3,465 | $1,188 | 34.3% |
| 94375 | Respiratory diagnostic testing (flow volume loop) | Office | 2021 | 21 | 26 | $1,768 | $811.75 | 45.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 14 | 15 | $1,200 | $678.00 | 56.5% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 17 | 18 | $1,872 | $663.34 | 35.4% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2021 | 60 | 83 | $498.00 | $175.50 | 35.2% |
About Dr. Leon Greos, MD
Dr. Leon Greos, MD is a Allergy & Immunology healthcare provider based in Centennial, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003887738.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leon Greos, MD has received a total of $25,159 in payments from pharmaceutical and medical device companies, with $27.92 received in 2023. These payments were reported across 62 transactions from 15 companies. The most common payment nature is "" ($20,284).
As a Medicare-enrolled provider, Greos has provided services to 1,731 Medicare beneficiaries, totaling 12,773 services with total Medicare billing of $132,006. Data is available for 3 years (2020–2022), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Centennial, CO
- Active Since 01/31/2006
- Last Updated 05/04/2021
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1003887738
Products in Payments
- Xhance (Drug) $2,815
- DUPIXENT (Drug) $1,800
- SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE (Drug) $1,500
- SYMBICORT (Drug) $51.65
- NUCALA (Biological) $42.83
- TRELEGY ELLIPTA (Drug) $42.19
- DUPIXENT (Biological) $36.77
- SPIRIVA RESPIMAT (Drug) $29.91
- Xolair (Biological) $29.18
- BREO (Drug) $28.46
- PANZYGA (Biological) $27.92
- FASENRA (Drug) $23.41
- Xembify (Biological) $22.58
- Prolastin-C Liquid (Biological) $22.49
- ProAir Digihaler (Drug) $19.71
- Auvi-Q (Drug) $18.44
- PROAIR (Drug) $18.28
- FASENRA (Biological) $17.07
- BREZTRI AEROSPHERE (Drug) $16.65
- SYMJEPI (Drug) $16.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.